• By ICR Secretariat
  • Posted Tuesday, September 20, 2022

How a top FDA official’s words helped push a closely watched ALS drug toward approval


The meeting was already unusual. Convened by the Food and Drug Administration Wednesday, a group of independent experts were, for a rare second time, gathering to review an experimental drug for ALS that has become the latest litmus test of the agency’s approval standards.